

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

UNITED STATES OF AMERICA

DECLARATION FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s).
I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Timing and Duration of Administration of Adenosine A1/A2 Agonist for Cardioprotection

and the specification of which ☐ is attached hereto (Aventis Docket No. USAV2001/0092 US CNT)
(check one) ☒ was filed on 10/29/2003 as U.S. Application Number 10/696,527
and was amended on (if applicable).
☐ was described and claimed in PCT Int'l Application Number filed on
and as amended under PCT Article 19 on (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification, including the claims as amended by any amendment referred to above.
I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 C.F.R. 1.56.

☒ I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one other country other than the United States of America, listed below and having a filing date before that of the application on which priority is claimed. I/We have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign Priority:	<u>0120124.3</u> Number	<u>United Kingdom</u> Country	<u>17/08/2001</u> Day/Month/Year Filed
----------------------	----------------------------	----------------------------------	---

Prior Foreign Appin(s):	Number	Country	Day/Month/Year Filed
-------------------------------	--------	---------	----------------------

☒ I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional application(s) listed below:

<u>60/288,938</u> Number	<u>May 4, 2001</u> Filing Date
-----------------------------	-----------------------------------

☒ I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States application(s) or international application designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

<u>PCT/US02/14228</u> Application Serial No.	<u>May 3, 2002</u> Filing Date	<u>Pending</u> Status (Patented, Pending)
---	-----------------------------------	--

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors(s): ☐ Additional names and signatures are attached.

1. Full name: Zhelong XU
Signature: *Zhelong XU*
Date: 12/4/03
Country of Citizenship: China
Residence: Chapel Hill, NC
(City and State/City and Country only)
P. O. Address: 114 Melville Loop #15
Chapel Hill, NC 27599

2. Full name: James M. DOWNEY
Signature: _____
Date: _____
Country of Citizenship: United States
Residence: Mobile, AL
(City and State/City and Country only)
P. O. Address: 1220 Anchor Drive
Mobile, AL 36693

UNITED STATES OF AMERICA

**DECLARATION
FOR PATENT APPLICATION**

As a below named inventor(s), I/We her by declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s).
I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed
and for which a patent is sought on the invention entitled:

Timing and Duration of Administration of Adenosine A1/A2 Agonist for Cardioprotection

and the specification of which ☐ is attached hereto (Aventis Docket No. **USAV2001/0082 US CNT**)
(check one) ☒ was filed on **10/29/2003** as U.S. Application Number **10/696,527**
and was amended on (if applicable).
☐ was described and claimed in PCT Int'l Application Number filed on
and as amended under PCT Article 19 on (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification,
including the claims as amended by any amendment referred to above.
I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to
be material to patentability as defined in 37 C.F.R. 1.56.

- ☒ I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign
application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at
least one other country other than the United States of America, listed below and having a filing date before that of
the application on which priority is claimed. I/We have also identified below any foreign application for patent or
inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign Priority:	0120124.3 Number	United Kingdom Country	17/08/2001 Day/Month/Year Filed
----------------------	----------------------------	----------------------------------	---

Prior Foreign Appln(s):	Number	Country	Day/Month/Year Filed
-------------------------------	--------	---------	----------------------

- ☒ I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional
application(s) listed below:

60/288,936 Number	May 4, 2001 Filing Date
-----------------------------	-----------------------------------

- ☒ I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States
application(s) or international application designating the United States listed below and, insofar as the subject
matter of each of the claims of this application is not disclosed in the prior United States application in the manner
provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose
information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which
became available between the filing date of the prior application and the national or PCT international filing date of
this application.

PCT/US02/14228 Application Serial No.	May 3, 2002 Filing Date	Pending Status (Patented, Pending)
---	-----------------------------------	--

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information
and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements
and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code §1001, and that such
willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventor(s): ☐ Additional names and signatures are attached.

1. Full name: **Zhelong XU**

Signature: _____


Date: _____

Country of Citizenship: **China**

Residence: **Chapel Hill, NC**
(City and State/City and Country only)

P. O. Address: **114 Melville Loop #15**
Chapel Hill, NC 27599

2. Full name: **James M. DOWNEY**

Signature: 

Date: **10 Dec 03**

Country of Citizenship: **United States**

Residence: **Mobile, AL**
(City and State/City and Country only)

P. O. Address: **1220 Anchor Drive**
Mobile, AL 36693

3. Full name: _____

Signature: _____

Date: _____

Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)P. O. Address: _____

4. Full name: _____

Signature: _____

Date: _____

Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)P. O. Address: _____

5. Full name: _____

Signature: _____

Date: _____

Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)P. O. Address: _____

6. Full name: _____

Signature: _____

Date: _____

Country of Citizenship: _____

Residence: _____
(City and State/City and Country only)P. O. Address: _____

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-3582
Telefax (908) 231-2626

Aventis Docket No. USA V2001/0092 US CNT



Aventis Docket No. USAV2001/0092 US CNT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: XU, et al.

Examiner: Not Yet Known

Serial No.: 10/696,527

Group Art Unit.:


Filed: October 29, 2003

Title: **Timing and Duration of Administration of
Adenosine A1/A2 Agonist for Cardioprotection****POWER OF ATTORNEY FOR PATENT APPLICATION**

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I, Ross J. Oehler, an Officer of Aventis Pharmaceuticals Inc., Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:

Customer No.: 005487

By: 
Ross J. Oehler

Title: Vice PresidentDate: 12/23/03

Address correspondence and telephone calls to:
Jiang Lin, Reg. No. 51,065
Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3582
Telefax (908) 231-2626